Literature DB >> 30229416

Prognostic Significance of Albumin-Globulin Score in Patients with Operable Non-Small-Cell Lung Cancer.

Xiang Li1, Sida Qin1, Xin Sun1, Dapeng Liu1, Boxiang Zhang1, Guodong Xiao1, Hong Ren2.   

Abstract

OBJECTIVE: This study was designed to evaluate the prognostic value of the preoperative albumin-globulin score (AGS) in the patients with non-small cell lung cancer (NSCLC) after pulmonary lobectomy. METHODS AND
RESULTS: The optimal cutoff level was 40.00 and 27.05 g/L for Alb and Glb, respectively. Based on this and the previous study, patients with both an hypoalbuminemia (< 40.00 g/L) and an elevated Glb level (≥ 27.05 g/L) were assigned a score of 2, and patients with one or neither were assigned a score of 1 or 0, respectively. We investigated the correlations between the AGS and the clinicopathological characteristics of patients and found that AGS was significantly associated with TNM stage (P = 0.016). Multivariate Cox analyses indicated that the AGS was an independent prognostic indicator for NSCLC for disease-free survival (DFS) (P = 0.001) and overall survival (OS) (P = 0.004). Kaplan-Meier analysis and log-rank test demonstrated that there were significant differences in DFS (P < 0.001) and OS (P < 0.001) among the three AGS groups. Furthermore, our study showed that DFS and OS are significantly different in three groups of patients with different AGS, in both Squamous carcinoma (P < 0.001 for DFS; P < 0.001 for OS) or adenocarcinoma (P = 0.034 for DFS; P = 0.035 for OS). In addition, we enrolled 53 patients as an independent set of cases for the further validation of AGS. Multivariate analyses verified AGS was an independent prognostic factor for NSCLC patients (P = 0.020 for DFS; P = 0.018 for OS).
CONCLUSIONS: Preoperative AGS is an independent prognostic factor for patients with operable NSCLC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30229416     DOI: 10.1245/s10434-018-6715-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis.

Authors:  Wen Fu; Kun Wang; Shan Yan; Xie Wang; Bo Tang; Jiang Chang; Ran Wang; Tao Wu
Journal:  Dose Response       Date:  2020-08-03       Impact factor: 2.658

2.  Acute Toxicities and Prognosis of Elderly Patients with Nasopharyngeal Carcinoma After Intensity-Modulated Radiotherapy: Prediction with Nomogram.

Authors:  Yu Liang; Kai-Hua Chen; Jie Yang; Jing Zhang; Ru-Rong Peng; Song Qu; Ling Li; Xiao-Dong Zhu
Journal:  Cancer Manag Res       Date:  2020-09-22       Impact factor: 3.989

3.  Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients.

Authors:  Xin Lu; Wanying Guo; Wei Xu; Xuelei Zhang; Zhijie Shi; Leizhen Zheng; Wenzhao Zhao
Journal:  Cancer Manag Res       Date:  2018-12-24       Impact factor: 3.989

4.  Combination of Total Psoas Index and Albumin-Globulin Score for the Prognosis Prediction of Bladder Cancer Patients After Radical Cystectomy: A Population-Based Study.

Authors:  Keyi Wang; Yongzhe Gu; Jinliang Ni; Houliang Zhang; Jinbo Xie; Tianyuan Xu; Jiang Geng; Weipu Mao; Bo Peng
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

5.  Development of nomograms related to inflammatory biomarkers to estimate the prognosis of bladder cancer after radical cystectomy.

Authors:  Wentao Zhang; Fuhan Yang; Aimaitiaji Kadier; Yifan Chen; Yang Yu; Junfeng Zhang; Jiang Geng; Yang Yan; Wei Li; Xudong Yao
Journal:  Ann Transl Med       Date:  2021-09

6.  Prognostic Value of Glasgow Prognostic Score in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chuan-Long Zhang; Kui Fan; Meng-Qi Gao; Bo Pang
Journal:  Pathol Oncol Res       Date:  2022-02-15       Impact factor: 3.201

7.  A novel nutritional score based on serum triglyceride and protein levels predicts outcomes of intrahepatic cholangiocarcinoma after curative hepatectomy: A multi-center study of 631 patients.

Authors:  Yunshi Cai; Shuai Xue; Jiaxin Li; Heng Xiao; Tian Lan; Hong Wu
Journal:  Front Nutr       Date:  2022-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.